Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

pany and our ongoing efforts to manage expenses.

Collaborative profit sharing, which represents Lilly's share of the gross margin for BYETTA, was $43.1 million for the quarter ended December 31, 2011, compared to $63.1 million for the same period in 2010. The decrease is due primarily to the termination of the Lilly collaboration resulting in the termination of gross profit sharing with Lilly in the U.S. effective December 1, 2011.

Net costs to reacquire economic interest in exenatide products totaled $431.6 million and consist primarily of reacquired marketing rights for unapproved products in the U.S. and are offset by gains associated with the termination of the collaboration with Lilly.  

Interest and other expense, net, increased to $31.7 million for the quarter ended December 31, 2011 from $8.9 million for the same period in 2010. The increase primarily reflects increased interest expense on the Company's debt, resulting from the promissory note related to the revenue sharing obligation (RSO) entered into in connection with the Settlement Agreement, and a loss on a fair value adjustment to a derivative asset.

Non-GAAP operating income was $17.6 million for the quarter ended December 31, 2011 compared to $22.9 million for the same period in 2010. GAAP net loss was $461.5 million, or $3.15 per share, for the quarter ended December 31, 2011, compared to GAAP net loss of $19.2 million, or $0.13 per share, for the same period in 2010.

Year Ended December 31, 2011Total revenues for the twelve months ended December 31, 2011 were $650.7 million. This includes net product sales of $621.6 million, including $517.7 million for BYETTA and $103.9 million for SYMLIN. This compares to net product sales of $651.1 million, consisting of $559.3 million for BYETTA and $91.8 million for SYMLIN for the same period in 2010.

Revenues under collaborative agreements were $29.1 million for the twelve months ended December 31, 2011, and
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 19, 2013 ... Parkinson,s disease (PD) patients as add-on to levodopa ... improvement in motor symptoms in fluctuating PD patients ... Newron Pharmaceuticals S.p.A. ("Newron"), a research and ... therapies, and its partner Zambon S.p.A., a pharmaceutical ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... Novel System May Provide Cancer Patients With ... April 16, 2007 /PRNewswire/ -- Insert,Therapeutics, Inc., ... today its novel delivery system,called Cyclosert(TM) will ... 2007 American Association for Cancer Research (AACR) ...
... WIRE)--Apr 16, 2007 - Novelos,Therapeutics, Inc. (OTCBB: ... of therapeutics to treat cancer and,hepatitis, today ... Kenneth Tew and Dr. Danyelle Townsend of ... making two poster presentations at the,ongoing American ...
Cached Medicine Technology:Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting 2
(Date:6/18/2013)... St. Petersburg, FL (PRWEB) June 19, 2013 ... only 5 minutes a day could boost your health ... says Kathy Heshelow, founder of Sublime Beauty®. "It is ... been practiced for centuries but became a lost art. ... and celebrities know about Skin Brushing, and so do ...
(Date:6/18/2013)... PA, June 19, 2013 Recent studies linking ... of bullying-related suicide among young people, led the ... assemble an expert panel to focus on these ... the complex relationship between youth involvement in bullying ... among youth is a significant public health problem, ...
(Date:6/18/2013)... York (PRWEB) June 19, 2013 Parker ... the rights of victims injured by dangerous drugs and ... an Arizona woman who alleges that she was ... filed on May 30th in the U.S. District Court ... No. 2:13-cv-12677) in the multidistrict litigation entitled In Re: ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Bullying and suicide among youth is a public health problem 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
... anthrax outbreak has led to the quarantine of about ... among animals through contaminated feed, pasture or soil during ... Agency (CFIA) has given the green signal for vaccination ... However some veterinarians in private practice, have run out ...
... to have reached, and exceeded, its medical recruitment targets ... need// for an additional $5 billion for mental health ... to employ400 more allied health professionals, 500 more nurses ... ,According to Health Minister Stephen Robertson the new ...
... concluded that persons who live alone are twice as ... compared to people// who live with partners, or families. ... colleagues, of the Aarhus Sygehus University Hospital in Denmark, ... the ages of 30-69. Their findings on the study ...
... ministry of health and family welfare for the coveted ... health promotion and tobacco control"//. ,Minister of Health ... at a ceremony during the World Conference on Tobacco ... ,The award has been conferred on the ministry ...
... of South African Indian Siamese twins are doing well and are ... Lowton, born on June 21 at the Arwyp Medical Centre here, ... gaining weight and are healthy," a report in the Post newspaper ... ,The twins, who are joined above the ear, were born ...
... Providing a rich source of live-saving stem cells, seven banks ... the first of the series will open in Gurgaon this// ... a US body, and R.J. Corporation headed by Ravi Jaipuria, ... metro cities. ,Cryobanks International is a leader ...
Cached Medicine News:Health News:Queensland Government to Meet its Medical Targets 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2Health News:First Cord Blood Bank in North India to be Opened in Gurgaon 2
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left. Most popular size or model....
Angled shafts with 11 mm long tips. Jaws have longitudinal meshing serrations. Slide lock and serrated handle with polished finish....
Multi-curved shafts with straight blades and longitudinal serrations. Slide lock and serrated handle with polished finish. Blade length: 27 mm....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Medicine Products: